GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVie Inc (NAS:BIVI) » Definitions » Cyclically Adjusted Price-to-FCF

BioVie (BioVie) Cyclically Adjusted Price-to-FCF : (As of May. 17, 2024)


View and export this data going back to 2014. Start your Free Trial

What is BioVie Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioVie Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BioVie's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVie Cyclically Adjusted Price-to-FCF Chart

BioVie Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioVie Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioVie's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, BioVie's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVie's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioVie's Cyclically Adjusted Price-to-FCF falls into.



BioVie Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BioVie's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, BioVie's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.155/129.4194*129.4194
=-0.155

Current CPI (Dec. 2023) = 129.4194.

BioVie Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.089 99.695 -0.116
201406 -0.017 100.560 -0.022
201409 -0.021 100.428 -0.027
201412 -0.043 99.070 -0.056
201503 -0.014 99.621 -0.018
201506 -0.016 100.684 -0.021
201509 -0.003 100.392 -0.004
201512 -0.023 99.792 -0.030
201603 -0.023 100.470 -0.030
201606 -0.171 101.688 -0.218
201609 -0.183 101.861 -0.233
201612 -0.146 101.863 -0.185
201703 -0.367 102.862 -0.462
201706 -0.170 103.349 -0.213
201709 -0.272 104.136 -0.338
201712 -0.211 104.011 -0.263
201803 -0.063 105.290 -0.077
201806 -0.267 106.317 -0.325
201809 -0.179 106.507 -0.218
201812 -0.305 105.998 -0.372
201903 -0.260 107.251 -0.314
201906 -0.240 108.070 -0.287
201909 -0.143 108.329 -0.171
201912 -0.053 108.420 -0.063
202003 -0.077 108.902 -0.092
202006 -0.069 108.767 -0.082
202009 -0.182 109.815 -0.214
202012 -0.095 109.897 -0.112
202103 -0.075 111.754 -0.087
202106 -0.443 114.631 -0.500
202109 -0.107 115.734 -0.120
202112 -0.189 117.630 -0.208
202203 -0.236 121.301 -0.252
202206 -0.235 125.017 -0.243
202209 -0.339 125.227 -0.350
202212 -0.257 125.222 -0.266
202303 -0.332 127.348 -0.337
202306 -0.311 128.729 -0.313
202309 -0.331 129.860 -0.330
202312 -0.155 129.419 -0.155

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioVie  (NAS:BIVI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BioVie Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BioVie's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVie (BioVie) Business Description

Industry
Traded in Other Exchanges
N/A
Address
680 W Nye Lane, Suite 204, Carson, NV, USA, 89703
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Executives
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Cuong V Do director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Michael Edward Sherman director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Robert J Hariri director 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Joanne Wendy Kim officer: Chief Financial Officer C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Joseph M Palumbo other: Chief Medical Officer 616 BROOKSIDE AVENUE, SAINT DAVIDS PA 19087
Jonathan M Adams officer: EVP Liver Cirrhosis Programs 100 CUMMINGS CENTER 247C, BEVERLY MA 01915
Penelope Markham officer: EVP Liver Cirrhosis R&D C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Christopher Reading officer: EVP Neuroscience R&D C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Clarence N. Ahlem officer: EVP of Product Development 5305 RENAISSANCE AVE., SAN DIEGO CA 92122
Mina Sooch director 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Sigmund Rogich director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Patrick D Yeramian officer: Chief Medical Officer 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486